# Cabozantinib in Advanced Adrenocortical Carcinoma

> **NCT03612232** · PHASE2 · UNKNOWN · sponsor: **Wuerzburg University Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Adrenocortical Carcinoma

## Interventions

- **DRUG:** Cabozantinib-s-malate

## Key facts

- **NCT ID:** NCT03612232
- **Lead sponsor:** Wuerzburg University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-04
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-04-30
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03612232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03612232, "Cabozantinib in Advanced Adrenocortical Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03612232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*